Institute for Neurodegenerative Disorders

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.

  NCT07830654· Phase 2· Michael J. Fox Foundation for Parkinson's Research· Source

• Recruiting

  A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's Disease

  NCT07809438· Phase 2· Michael J. Fox Foundation for Parkinson's Research· Source

• Recruiting

  A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

  NCT06565195· Phase 1· Prevail Therapeutics· Source

• Recruiting

  Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

  NCT07265596· Phase 2· Michael J. Fox Foundation for Parkinson's Research· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

  NCT04777331· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

  NCT04477785· Michael J. Fox Foundation for Parkinson's Research· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease6 recruiting

Closed trials

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

  NCT05063539· Phase 2· Eli Lilly and Company· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lewy body dementia8 works · 0 trials